Therapeutic drug monitoring of voriconazole and posaconazole.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveInvasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational sPosaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepinePlasma Voriconazole Estimation by HPLC.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Comparison of clinical pharmacology of voriconazole and posaconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Safety and interactions of new antifungals in stem cell transplant recipients.Individualization of drug therapy: history, present state, and opportunities for the future.A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, AsAntimicrobial stewardship in patients with cancer.Safety of posaconazole.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Targeting CYP51 for drug design by the contributions of molecular modeling.Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxisClinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Successful long-term management of invasive cerebral fungal infection following liver transplantation.Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.Preemptive treatment with voriconazole in lung transplant recipients.Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).Simultaneous determination of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection.
P2860
Q27009221-206B7451-2D91-4524-8D6D-3C2425000260Q34288593-45BCE287-B946-4466-9D53-280E332F7655Q35262607-9487199A-FA0F-4BF4-A98A-60FDB10E6892Q36088030-9697AE51-45AD-4DE8-975C-14F8BF7B31EFQ36764126-AB0333F8-4C29-4B0D-9338-0A0628760BF5Q36849416-8AC15A06-529C-4BFB-8008-3DF6E0FA884EQ37727651-9AE0EE3B-E70D-4A94-A593-691C825323AAQ37904672-10DA737B-5B35-4631-B8CE-5156C2F8C0FFQ38036740-E561858B-6AC5-414A-9189-999B3AA4958EQ38040697-540B65E6-F369-4417-8584-A39494DCBB70Q38049498-5D0683C5-675E-4F39-AD8F-12F1C930F4D5Q38073198-6CFF37CA-35C2-4157-A3BC-1474067ABC0EQ38077591-34B22DA7-C6CF-4B16-B33C-55908DE339E6Q38284468-19961FFB-97A4-4F9C-B378-50435F04754FQ38917135-9F8C4CE9-8635-43C5-BB1E-B8FB68DDDF6CQ39471624-26D2AF88-1BA2-41CC-A8B1-946B7A235A4EQ40267497-BEC305D5-85B4-43EB-9B40-7BF1E4855C8FQ40577292-BCEA59A5-8A13-4AB6-9A1A-D07FD2AC2CAEQ41543346-0EA0EA80-EAFC-451C-8D86-4C8CB7DE5A44Q41708603-C8E537E7-0966-46CB-802E-6B6C5130492DQ44239236-D228A955-6582-4009-8E5B-DBF0D6AF9F8EQ45158220-16244485-24FD-46D8-AE2E-B0F4271989BFQ45160680-5376A17A-EEC6-417A-81F2-BF91BE094C7AQ48155956-737256F6-1DF2-4819-AA1B-6B20EA7B1D17Q53139358-4377AAA7-5A0E-4523-A12A-12125FA3539E
P2860
Therapeutic drug monitoring of voriconazole and posaconazole.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic drug monitoring of voriconazole and posaconazole.
@en
Therapeutic drug monitoring of voriconazole and posaconazole.
@nl
type
label
Therapeutic drug monitoring of voriconazole and posaconazole.
@en
Therapeutic drug monitoring of voriconazole and posaconazole.
@nl
prefLabel
Therapeutic drug monitoring of voriconazole and posaconazole.
@en
Therapeutic drug monitoring of voriconazole and posaconazole.
@nl
P2093
P2860
P356
P1433
P1476
Therapeutic drug monitoring of voriconazole and posaconazole.
@en
P2093
Fedja Farowski
Janne J Vehreschild
Maria J G T Rüping
P2860
P304
P356
10.1592/PHCO.31.2.214
P407
P577
2011-02-01T00:00:00Z